Navigating Ortho's Choppy Seas: An Interview with Zimmer's David Dvorak
Executive Summary
Since becoming CEO of orthopedics giant Zimmer two years ago, David Dvorak has faced a host of challenges unprecedented in this booming market, including a federal investigation into and settlement of questionable relationships with customers and the most severe economic crisis in 30 years. But Dvorak seems calm and confident as he looks ahead.
You may also be interested in...
The New Math Of Ortho Innovation – An Interview With Zimmer CEO David Dvorak
After emerging from the DOJ settlements, the leading pure-play orthopedics company is emphasizing – and redefining – innovation to drive growth. Zimmer CEO David Dvorak talks to IN VIVO about his company’s commitment to innovation, and how the very notion of innovation is changing.
Biomet Roars Back
Five years ago, Biomet was in turmoil, as the board announced the company was for sale and the company's long-time CEO stepped down. The eventual buyers: a group of leading private equity firms. Biomet still faced a number of internal challenges, including fixing a spine and trauma business that was performing poorly. Critical to Biomet's turnaround was re-establishing the culture of stability that had long characterized the company. At the same time, it now has a new, more aggressive focus on capturing market share commensurate with its role as a top orthopedics company.
Biomet Roars Back
Five years ago, Biomet was in turmoil, as the board announced the company was for sale and the company's long-time CEO stepped down. The eventual buyers: a group of leading private equity firms. Biomet still faced a number of internal challenges, including fixing a spine and trauma business that was performing poorly. Critical to Biomet's turnaround was re-establishing the culture of stability that had long characterized the company. At the same time, it now has a new, more aggressive focus on capturing market share commensurate with its role as a top orthopedics company.